Experimental Blood Test Could Flag Alzheimer’s Risk Years Before Symptoms

By the time most people receive an Alzheimer’s diagnosis, the damage to their brain has been building for decades. Symptoms like memory loss and confusion show up late in the disease, when treatments have far less power to help. But what if a blood draw could flag the risk nearly two decades before a person ever noticed anything was wrong?

That’s the promise behind new optical sensor technology described in a 2026 paper published in the Journal of Physical Chemistry B. Researchers developed a device called the immuno-infrared sensor, or iRS, that can detect the earliest molecular warning signs of both Alzheimer’s and Parkinson’s disease in blood, long before symptoms emerge. In studies cited by the researchers, the technology predicted clinical Alzheimer’s disease risk up to 17 years before diagnosis. It is not a routine screening test yet; the platform would need regulatory approval and significant scaling before it could be used widely.

Recently approved Alzheimer’s drugs work best at earlier stages of disease, which makes early detection especially important. Researchers argue that a widely available blood screening test could fundamentally change how society fights brain-wasting diseases in the elderly.

Why Early Detection of Alzheimer’s Is So Hard

Both Alzheimer’s and Parkinson’s are rooted in a process where proteins in the brain slowly change shape and stop working correctly. In Alzheimer’s, a protein called amyloid beta warps from its normal form into a twisted, clumped version that eventually forms plaques, but that destructive buildup is a late-stage development. Parkinson’s follows a similar pattern, where a different protein misfolds and accumulates in brain cells, and the disease is usually caught only after tremors and other movement problems appear.

Until now, the standard tools for catching these diseases early have had real drawbacks. Spinal taps can detect certain chemical markers but are invasive. Brain scans are more precise but expensive. Blood tests do exist, but the ones currently in use measure a protein concentration drop that only becomes detectable at later, more advanced stages.

How the Alzheimer’s Blood Test Sensor Actually Works

Rather than measuring whether a protein is present or absent, the iRS detects whether it has started to change shape, a much earlier warning sign. Healthy proteins and misfolded proteins absorb infrared light differently. By shining a precise laser at proteins captured from a blood or spinal fluid sample, the sensor determines how far along the misfolding process has gone.

Getting a clean signal is technically challenging. Water in blood absorbs infrared light at nearly the same wavelength used to measure the proteins, and its signal is vastly stronger. Researchers overcame this by engineering a sensor surface that probes only an extremely thin layer of fluid, about 500 nanometers thick, dramatically reducing water interference.

Specially designed antibodies on that surface act as molecular catchers, grabbing and concentrating only the specific protein of interest from the sample. A coating layer prevents anything else in the blood from sticking and muddying the signal. A laser then scans the captured proteins, and the position of the light absorption reading reveals the degree of misfolding.

What the Studies Found About Alzheimer’s and Parkinson’s Risk

The paper is a perspective article that synthesizes findings from previously published research. One large population-based study involving blood samples from a subset of 10,000 participants found that the iRS predicted Alzheimer’s disease risk up to 17 years before any symptoms appeared, with accuracy reaching as high as 0.82 out of a possible 1.0. Among a smaller group who already reported subtle memory concerns, the test predicted conversion to full clinical Alzheimer’s disease six years in advance, with an accuracy score of 0.94.

For Parkinson’s disease, the sensor was applied to spinal fluid samples in a discovery and independent validation study, achieving 94% sensitivity and 97% specificity. Blood-based Parkinson’s results were also reported, with an accuracy score of 0.94, 87% sensitivity, and 97% specificity, though that study was a preprint at the time and had not yet completed peer review.

Could This Test Become a Routine Alzheimer’s Screening Tool?

For the technology to reach everyday use, researchers say it will need regulatory approval, including FDA clearance in the United States. Their stated goal is a blood test offered broadly to people over 60, the age group where risk rises sharply. A newer version of the instrument already runs four measurement channels simultaneously and is being miniaturized, progress the researchers say is essential for processing enough samples to screen a population.

Researchers also suggest that p-tau 217, an established blood marker for clinical-stage Alzheimer’s, and the iRS could eventually be used together: p-tau 217 screening a large pool of samples, with the iRS providing a more detailed read on those who test positive. The lead corresponding author, Klaus Gerwert, is the founder and CEO of betaSENSE GmbH, connected to the commercialization of this technology, a relationship the paper discloses as a competing financial interest.

Millions of Americans are living with Alzheimer’s or Parkinson’s, and millions more will develop these diseases as the population ages. Treatments have advanced, but they work best when the disease is caught earliest. A test that could reliably flag risk many years before symptoms appear would give patients and families something they currently don’t have: time.

---

Disclaimer: This article is based on a perspective paper, a format that reviews and synthesizes previously published research rather than presenting new clinical trial data. The technology described has not received regulatory approval and is not available as a routine medical test. Findings should not be interpreted as medical advice.

---